Tirzepatide TFA (2023788-19-2 free base)
CAS No. ——
Tirzepatide TFA (2023788-19-2 free base) ( LY3298176 TFA )
产品货号. M29808 CAS No. ——
Tirzepatide TFA (LY3298176 TFA) is a disaccharide dependent insulin peptide (GIP) and glucagon-like peptide-1 (glp-1) receptor agonist.
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
规格 | 价格/人民币 | 库存 | 数量 |
100MG | 获取报价 | 有现货 |
|
200MG | 获取报价 | 有现货 |
|
500MG | 获取报价 | 有现货 |
|
100MG | 获取报价 | 有现货 |
|
200MG | 获取报价 | 有现货 |
|
500MG | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Tirzepatide TFA (2023788-19-2 free base)
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述Tirzepatide TFA (LY3298176 TFA) is a disaccharide dependent insulin peptide (GIP) and glucagon-like peptide-1 (glp-1) receptor agonist.
-
产品描述Tirzepatide TFA (LY3298176 TFA) is a disaccharide dependent insulin peptide (GIP) and glucagon-like peptide-1 (glp-1) receptor agonist.
-
同义词LY3298176 TFA
-
通路Others
-
靶点Other Targets
-
受体Glucose-dependent insulinotropic polypeptide (GIP), GLP-1 receptor
-
研究领域——
-
适应症——
化学信息
-
CAS Number——
-
分子量4927.5
-
分子式C227H349F3N48O70
-
纯度>98% (HPLC)
-
溶解度——
-
SMILES——
-
化学全称Sequence:Tyr-{Aib}-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-{Aib}-Leu-Asp-Lys-Ile-Ala-Gln-{diacid-gamma-Glu-(AEEA)2-Lys}-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
Frias JP, et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet. 2018 Nov 17;392(10160):2180-2193.
产品手册
关联产品
-
NMS-P937
NMS-P937 (NMS1286937), an oral, specific Polo-like Kinase 1 (PLK1) inhibitor, is with IC50 of 2 nM. The specificity of NMS-P937 forPLK1 is 5000-fold higher over PLK2/PLK3.
-
Super-TDU (TFA) (159...
uper-TDU is an inhibitory peptide targeting YAP-TEADs interaction.
-
Methyl nomilinate
Methyl nomilinate from citrus can modulate cell cycle regulators to induce cytotoxicity in human colon cancer (SW480) cells in vitro.